Aligos Therapeutics, Inc. announced that it has entered into an exclusive license and research collaboration agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) under which MSD and Aligos will apply Aligos’ oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a non-alcoholic steatohepatitis (NASH) target and up to one additional target of interest in the cardiometabolic/fibrosis space.
